PIAE risk minimized by additional treatment

Article

Treatment of blepharitis before injection, avoidance of subconjunctival anaesthesia and topical antibiotic administration immediately after injection all contribute to minimizing the risk of contracting post-intravitreal anti-VEGF endophthalmitis (PIAE).

Treatment of blepharitis before injection, avoidance of subconjunctival anaesthesia and topical antibiotic administration immediately after injection all contribute to minimizing the risk of contracting post-intravitreal anti-VEGF endophthalmitis (PIAE), claims a study in Eye.

Dr D. A. Lyall et al., Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, UK, conducted a prospective observational case control study on 47 patients with PIAE.

Patients were identified through the British Ophthalmological Surveillance Unit from January 2009 to March 2010 and data was gathered at diagnosis and at six months follow-up. The measures included patient demographics, intravitreal injection details, pre- and post-injection management, visual acuity, clinical features and management of PIAE, causative organisms and clinical outcomes. All subjects were compared to 200 control participants from 10 control centres to determine potential risk factors.

Positive microbiology culture was discovered in 59.6% of patients and the majority of causative organisms were Gram positive. The significant risk factors included failure to administer topical antibiotics immediately after the injection, blepharitis, subconjunctival anaesthesia, patient squeezing during the injection and failure to administer topical antibiotics before anti-VEGF injection.

The abstract can be viewed here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.